This is a disclosure report regarding financial/non-financial relationships with for-profit/non-profit healthcare organizations.
Pharmaceutical companies with potential conflict of interest
- Non-executive medical director: Octimet
- Stock options: Octimet
- Honoraria in the last 24 months: Basilea, Genmab, InteRNA, Octimet, and CoBioRes
Other affiliations with potential conflict of interest
- Board member: American Society of Clinical Oncology
- Chairman Governance Task Force: European Organisation for Research and Treatment of Cancer (From Feb 2020 onward)
Last updated on 24 May 2020